Boldenone vs Dianabol
Moderate Research vs Well Studied
avoid Mechanism-based · 60% Both Boldenone and Dianabol carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Boldenone Dianabol
Weight 286.41 Da (base) 300.44 Da
Half-life ~14 days (undecylenate) ~4-6 hours
Type 1-dehydrotestosterone steroid (C19H26O2) 17-alpha-alkylated anabolic steroid (C20H28O2)
Key Benefits
Boldenone
01 Lean, quality muscle gains with minimal water retention compared to testosterone
02 Enhanced vascularity through increased red blood cell production and reduced subcutaneous water
03 Significant increase in appetite, supporting caloric surplus during mass-gaining phases
04 Potent stimulation of erythropoiesis, increasing oxygen-carrying capacity and endurance
05 Lower estrogenic activity than testosterone, reducing the need for aromatase inhibitors
06 Lower androgenic side effects (hair loss, acne, prostate stimulation) than testosterone
07 Favorable anabolic-to-androgenic ratio (100:50 compared to testosterone at 100:100)
08 Improved collagen synthesis reported anecdotally, supporting joint and connective tissue health
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Dosing Protocols
Boldenone
200-400 mg/week (moderate) / 1-2x per week (undecylenate)
Lean Bulk - Moderate 200-400 mg/week 1-2x per week (undecylenate)
Performance Enhancement - Standard 400-600 mg/week 2x per week (undecylenate)
Performance Enhancement - High 600-700 mg/week 2x per week (undecylenate)
Boldenone Cypionate Protocol 200-400 mg/week Every 3-4 days
Dianabol
20-50 mg/day / Split doses throughout the day
Side Effects
Boldenone
Increased hematocrit and red blood cell count (the primary and most clinically significant side effect, more pronounced than with most other AAS)
Increased appetite (significant and dose-dependent, can be a benefit or hindrance depending on goals)
Anxiety and restlessness ('EQ anxiety' is widely reported anecdotally, particularly at higher doses or in anxiety-prone individuals)
Mild acne and oily skin (less than testosterone due to lower androgenic activity)
Suppression of endogenous testosterone production (profoundly suppressive, as with all AAS)
Mild hair thinning in genetically predisposed individuals (less than testosterone but not absent)
Elevated blood pressure secondary to increased blood volume from erythrocytosis
Increased vascularity (cosmetic effect, but indicative of elevated RBC)
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Contraindications
Polycythemia or elevated hematocrit (above 50% at baseline)
Cardiovascular disease, coronary artery disease, or history of thromboembolic events
Hepatic impairment or liver disease
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Pre-existing anxiety disorders (boldenone may significantly exacerbate anxiety symptoms)
Pregnancy or potential for pregnancy (Category X)
Known hypersensitivity to boldenone or any formulation components
Renal impairment (boldenone metabolites are renally cleared)
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Research Evidence
Boldenone Dianabol
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest January 2017 2017
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.